The reduction in price target by Needham suggests a slight decrease in the expected future stock price of Bicycle Therapeutics, which could lead to short-term negative sentiment among investors. However, the maintenance of a Buy rating indicates that the overall outlook remains positive, which could mitigate any negative impact. The score is neutral because the positive rating balances the reduced price target.